Filter Results
:
(22)
Show Results For
-
All HBS Web
(254)
- Faculty Publications (22)
Show Results For
-
All HBS Web
(254)
- Faculty Publications (22)
Page 1 of
22
Results
→
- July 2021
- Supplement
Adaptive Platform Trials: The Clinical Trial of the Future? (C)
By: Ariel D. Stern and Sarah Mehta
This (C) case provides an update on the work of the Global Coalition for Adaptive Research (GCAR) and also illustrates how adaptive platform trials can nimbly respond to a global pandemic.
View Details
Keywords:
Clinical Trials;
Drug Trials;
Drug Testing;
Cancer Trials;
Glioblastoma;
Platform Trials;
Adaptive Trials;
Adaptive Platform Trials;
Health Testing and Trials;
Health Care and Treatment;
Business Strategy;
Health Industry;
United States
Stern, Ariel D., and Sarah Mehta. "Adaptive Platform Trials: The Clinical Trial of the Future? (C)." Harvard Business School Supplement 622-012, July 2021.
- May 2021
- Article
Value-Based Healthcare in Urology: A Collaborative Review
By: Chanan Reitblat, Paul A. Bain, Michael E. Porter, David N. Bernstein, Thomas W. Feeley, Markus Graefen, Santosh Iyer, Matthew J. Resnick, C.J. Stimson, Quoc-Dien Trinh and Boris Gershman
Context:
In response to growing concerns over rising costs and major variation in quality, improving value for patients has been proposed as a fundamentally new strategy for how healthcare should be delivered, measured, and... View Details
In response to growing concerns over rising costs and major variation in quality, improving value for patients has been proposed as a fundamentally new strategy for how healthcare should be delivered, measured, and... View Details
Keywords:
Value-based Healthcare;
Integrated Practice Units;
Outcome Measurement;
Time-Driven Activity-Based Costing;
Health Care and Treatment;
Value;
Cost Management;
Strategy;
Outcome or Result;
Measurement and Metrics
Reitblat, Chanan, Paul A. Bain, Michael E. Porter, David N. Bernstein, Thomas W. Feeley, Markus Graefen, Santosh Iyer, Matthew J. Resnick, C.J. Stimson, Quoc-Dien Trinh, and Boris Gershman. "Value-Based Healthcare in Urology: A Collaborative Review." European Urology 79, no. 5 (May 2021): 571–585.
- March 2021 (Revised January 2023)
- Case
The Trouble with TCE
By: Vincent Pons, Rafael Di Tella and Galit Goldstein
Trichloroethylene, or TCE, was a chemical used by tens of thousands of businesses in the United States. It was an affordable tool for many. Yet, TCE had been associated with important health risks, including cancer and autoimmune disease. TCE potentially posed other...
View Details
Keywords:
Trichloroethylene;
Toxicity;
Lobbying;
Chemicals;
Health Disorders;
Governing Rules, Regulations, and Reforms;
Policy;
Ethics;
Business and Government Relations;
Chemical Industry;
United States
Pons, Vincent, Rafael Di Tella, and Galit Goldstein. "The Trouble with TCE." Harvard Business School Case 721-031, March 2021. (Revised January 2023.)
- December 2020 (Revised April 2021)
- Case
IBM Watson at MD Anderson Cancer Center
By: Shane Greenstein, Mel Martin and Sarkis Agaian
After discovering that their cancer diagnostic tool, designed to leverage the cloud computing power of IBM Watson, needed greater integration into the clinical processes at the MD Anderson Cancer Center, the development team had difficult choices to make. The Oncology...
View Details
Keywords:
Decision Making;
Innovation Strategy;
Knowledge Management;
Knowledge Use and Leverage;
Operations;
Failure;
Information Technology;
Applications and Software;
Health Care and Treatment;
Product Development;
Health Industry;
Information Technology Industry;
Technology Industry;
United States;
Houston;
Texas
Greenstein, Shane, Mel Martin, and Sarkis Agaian. "IBM Watson at MD Anderson Cancer Center." Harvard Business School Case 621-022, December 2020. (Revised April 2021.)
- December 2019
- Technical Note
Technical Note on Bayesian Statistics and Frequentist Power Calculations
By: Amitabh Chandra and Ariel Dora Stern
This Technical Note provides an introduction to Bayes’ Rule and the statistical intuition that stems from it. In this note, we review the concepts that underlie Bayesian statistics, and we offer several simple mathematical examples to illustrate applications of Bayes’...
View Details
Chandra, Amitabh, and Ariel Dora Stern. "Technical Note on Bayesian Statistics and Frequentist Power Calculations." Harvard Business School Technical Note 620-032, December 2019.
- September 2017 (Revised February 2023)
- Case
Intermountain Healthcare: Pursuing Precision Medicine
By: Richard G. Hamermesh, Kathy E. Giusti, Robert S. Huckman and Julia Kelley
Headquartered in Salt Lake City, Intermountain Healthcare operates 23 hospitals and hundreds of clinics in Utah and Idaho and provides insurance to approximately 850,000 patients through its insurance arm, SelectHealth. In 2013, Intermountain, known for its commitment...
View Details
Keywords:
Precision Medicine;
Healthcare;
Innovation;
Cancer;
Cancer Research;
Health Care;
Technology;
Health Care and Treatment;
Innovation Leadership;
Disruptive Innovation;
Entrepreneurship;
Decision Choices and Conditions;
Health Industry;
Insurance Industry;
Utah;
United States;
North America
Hamermesh, Richard G., Kathy E. Giusti, Robert S. Huckman, and Julia Kelley. "Intermountain Healthcare: Pursuing Precision Medicine." Harvard Business School Case 818-018, September 2017. (Revised February 2023.)
- September 2017 (Revised January 2018)
- Case
Adaptive Platform Trials: The Clinical Trial of the Future?
By: Ariel D. Stern and Sarah Mehta
In July 2017, Dr. Brian M. Alexander, president and CEO of the AGILE Research Foundation, was preparing to launch a new type of clinical trial—an adaptive platform trial—to study potential therapies for glioblastoma (GBM), an aggressive form of brain cancer....
View Details
Keywords:
Clinical Trials;
Cancer;
Adaptive Platform Trials;
Platform Trials;
Adaptive Trials;
Glioblastoma;
Health;
Health Care and Treatment;
Health Testing and Trials;
Business Strategy;
Innovation Strategy;
Health Industry;
United States
Stern, Ariel D., and Sarah Mehta. "Adaptive Platform Trials: The Clinical Trial of the Future?" Harvard Business School Case 618-025, September 2017. (Revised January 2018.)
- January 12, 2017
- Article
What Cancer Researchers Can Learn from Direct-to-Consumer Companies
By: Richard G. Hamermesh and Kathryn E. Giusti
Hamermesh, Richard G., and Kathryn E. Giusti. "What Cancer Researchers Can Learn from Direct-to-Consumer Companies." Harvard Business Review (website) (January 12, 2017).
- Article
One Obstacle to Curing Cancer: Patient Data Isn't Shared
By: Richard G. Hamermesh and Kathy Giusti
Precision Medicine requires large datasets to identify the mutations that lead to various cancers. Currently, genomic information is hoarded in fragmented silos within numerous academic medical centers, pharmaceutical companies, and some disease-based foundations. For...
View Details
Keywords:
Healthcare;
Technological And Scientific Innovation;
Cancer Care In The U.S.;
Cancer Treatment;
Precision Medicine;
Personalized Medicine;
Data Sharing;
Technological Innovation;
Analytics and Data Science;
Health Disorders;
Medical Specialties;
Research and Development;
Customization and Personalization;
Health Industry;
United States
Hamermesh, Richard G., and Kathy Giusti. "One Obstacle to Curing Cancer: Patient Data Isn't Shared." Harvard Business Review (website) (November 28, 2016).
- December 2014 (Revised January 2016)
- Case
Vanderbilt: Transforming a Health Care Delivery System
By: Michael E. Porter, Zachary C. Landman and Derek A. Haas
In 2013, Vanderbilt University Medical Center was the top ranked hospital in Tennessee by U.S. News and World Report, and among the leading academic medical centers in the entire southeast region. The 2012 US News & World Report hospital rankings listed Vanderbilt's...
View Details
Keywords:
Health Care;
Health Care Industry;
Service Delivery;
Transformation;
Health Care and Treatment;
Corporate Strategy;
Health Industry;
Tennessee
Porter, Michael E., Zachary C. Landman, and Derek A. Haas. "Vanderbilt: Transforming a Health Care Delivery System." Harvard Business School Case 715-440, December 2014. (Revised January 2016.)
- June 2014 (Revised February 2017)
- Case
Kathy Giusti and the Multiple Myeloma Research Foundation
By: Richard G. Hamermesh, Joshua D. Margolis and Matthew G. Preble
What do you do when your rising professional career is cut short by an unexpected cancer diagnosis? Kathy Giusti shifted careers, built a new organization that transformed how cancer research is done, and now faces the challenge of sustaining the organization and its...
View Details
Keywords:
Philanthropy;
Philanthropy Funding;
Entrepreneurship;
Health Care;
Management Styles;
Personalized Medicine;
Health Care Outcomes;
Cancer;
Cancer Care In The U.S.;
Personal Care;
Leadership;
Leading Change;
Social Entrepreneurship;
Philanthropy and Charitable Giving;
Health Care and Treatment;
Leadership Style;
Management Style;
Management Skills;
Growth and Development Strategy;
Business Strategy;
Health;
Health Industry;
United States;
Canada;
Spain
Hamermesh, Richard G., Joshua D. Margolis, and Matthew G. Preble. "Kathy Giusti and the Multiple Myeloma Research Foundation." Harvard Business School Case 814-026, June 2014. (Revised February 2017.)
- May 2014
- Case
Health Care Accountability: Examples in Cancer Treatment
By: Regina E. Herzlinger and Natalie Kindred
This case is designed to support a discussion of the importance of outcomes evidence in empowering the public to make better health care decisions, the desired level of transparency and accountability for health care providers, and the issues with current measuring and...
View Details
Keywords:
Accountability;
Health Care;
Cancer;
Cancer Treatment;
Memorial Sloan Kettering Cancer Center;
Cancer Treatment Centers Of America;
Vantage Oncology;
Radiology;
Risk Adjustment;
Treatment Outcomes;
Health Care Outcomes;
Prostate Cancer;
Transparency;
Health Care and Treatment;
Risk Management;
Outcome or Result;
Health Industry;
United States
- January 2014 (Revised March 2014)
- Teaching Note
Cancer Screening in Japan: Market Research and Segmentation
By: John A. Quelch
- January 2014 (Revised March 2014)
- Case
Cancer Screening in Japan: Market Research and Segmentation
By: John A. Quelch and Margaret L. Rodriguez
Since founding CancerScan in 2008, Jun Fukuyoshi and Yoshiki Ishikawa had helped to improve cancer screening rates in Japan. Between 2005 and 2007, awareness of breast cancer in Japan rose from 55% to 70%, but the incidence of breast cancer screenings remained...
View Details
Quelch, John A., and Margaret L. Rodriguez. "Cancer Screening in Japan: Market Research and Segmentation." Harvard Business School Case 514-057, January 2014. (Revised March 2014.)
- October 2013
- Case
FasterCures: Removing Barriers to Treatments
By: Richard G. Hamermesh and James Weber
In mid-2013, as FasterCures celebrated its 10th anniversary as a center of the Milken Institute, Executive Director Margaret Anderson thought about what the organization should do to ensure it had even more impact in its next 10 years. FasterCures was a non-profit... View Details
Keywords:
Health Care;
Health Care Industry;
Health Care Policy;
Health Services;
Healthcare;
Healthcare Reform;
Healthcare Ventures;
Nonprofit;
Non-profit Management;
Not-for-profit;
Incubator;
Accelerator;
Venture Philanthropy;
Medical Services;
Medical Solutions;
Medical Research;
Medical Treatment;
Clinical Trials;
Drug Reimbursement;
Early Stage;
Early Stage Research Funding;
Early Stage Funding;
Milken Institute;
Michael Milken;
David Baltimore;
Partnering For Cures;
National Institutes Of Health;
Cancer Care In The U.S.;
Cancer Care Services;
Policy-making;
Health Care and Treatment;
Health;
Health Testing and Trials;
Entrepreneurship;
Social Entrepreneurship;
Nonprofit Organizations;
Policy;
Health Industry;
United States;
District of Columbia
Hamermesh, Richard G., and James Weber. "FasterCures: Removing Barriers to Treatments." Harvard Business School Case 814-003, October 2013.
- July 2011 (Revised September 2012)
- Case
Intraoperative Radiotherapy for Breast Cancer (A)
By: Willy Shih
"This trial is going to take longer." Those were words that Michael Kaschke, CEO of Carl Zeiss AG, was not surprised to hear as he nurtured the intraoperative radiotherapy business inside his company's microsurgery unit. But he also didn't expect it to take 13 years to...
View Details
Keywords:
Finance;
Business History;
Disruptive Innovation;
Emerging Markets;
Organizational Change and Adaptation;
Research and Development;
Safety
Shih, Willy. "Intraoperative Radiotherapy for Breast Cancer (A)." Harvard Business School Case 612-003, July 2011. (Revised September 2012.)
- May 2008 (Revised April 2018)
- Case
The University of Texas MD Anderson Cancer Center: Interdisciplinary Cancer Care
By: Michael E. Porter and Sachin H. Jain
In 2006, University of Texas MD Anderson Cancer Center was an internationally leading institution for cancer care, education, and research. Since 1996, it had successfully reorganized itself from a cancer hospital that was physically organized around clinical...
View Details
Keywords:
Buildings and Facilities;
Health Disorders;
Organizational Structure;
Medical Specialties;
Organizational Change and Adaptation;
Value Creation;
Service Delivery;
Research;
Health Care and Treatment;
Education Industry;
Health Industry;
Texas
Porter, Michael E., and Sachin H. Jain. "The University of Texas MD Anderson Cancer Center: Interdisciplinary Cancer Care." Harvard Business School Case 708-487, May 2008. (Revised April 2018.)
- December 2003
- Case
Manville Corporation Fiber Glass Group (C) (Abridged)
By: Lynn S. Paine
Manville Corp.'s senior managers are surprised when Japanese government officials advise them not to go forward with their plan to add a cancer warning label to diatomaceous earth (DE) products sold in Japan. The International Agency for Research on Cancer has ruled...
View Details
Keywords:
Risk and Uncertainty;
Moral Sensibility;
Safety;
Government Administration;
Cross-Cultural and Cross-Border Issues;
Decision Choices and Conditions;
Ethics;
Announcements;
Industrial Products Industry;
Japan
Paine, Lynn S. "Manville Corporation Fiber Glass Group (C) (Abridged)." Harvard Business School Case 304-078, December 2003.
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the...
View Details
Keywords:
Decision Making;
Health Testing and Trials;
Innovation and Invention;
Markets;
Distribution;
Product Development;
Production;
Problems and Challenges;
Research;
Research and Development;
Complexity;
Biotechnology Industry;
Pharmaceutical Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
- February 1994 (Revised May 1999)
- Case
Manville Corp. Fiber Glass Group (C)
By: Lynn S. Paine and Sarah Gant
Manville Corp.'s senior managers are surprised when Japanese government officials advise them not to go forward with their plan to add a cancer warning label to diatomaceous earth (DE) products sold in Japan. The International Agency for Research on Cancer has ruled...
View Details
Keywords:
Management Teams;
Ethics;
Conflict of Interests;
Health;
Safety;
Cross-Cultural and Cross-Border Issues;
Policy;
Japan
Paine, Lynn S., and Sarah Gant. "Manville Corp. Fiber Glass Group (C)." Harvard Business School Case 394-116, February 1994. (Revised May 1999.)